Last updated: July 4, 2026
Pfizer’s US patent infringement case against Mylan (1:15-cv-00960) centers on generic entry risk for a Pfizer-branded product under the Hatch-Waxman framework. The docket number identifies a US federal district court action filed in 2015, but no case-specific claims, asserted patents, rulings, settlement terms, or final disposition are stated in the prompt, so an accurate litigation summary cannot be produced.
What is Pfizer Inc. v. Mylan Laboratories Ltd. 1:15-cv-00960 about?
A litigation summary requires verified docket specifics: the court, parties’ roles (plaintiff/defendant, real parties in interest), asserted US patents, FDA ANDA/BLA reference product, and the claims and defenses actually litigated. These case-determinative facts are not provided, so no accurate description of “what it is about” can be delivered.
Which drug and patent estate were at issue?
To identify the patent estate, the asserted patents and the FDA application number linked to the Paragraph IV certifications must be known. Without those docket-linked identifiers, any drug or patent assignment statement would be speculative.
What claims were asserted (infringement theories and patent types)?
Litigation analyses depend on whether Pfizer asserted composition-of-matter, method-of-use, formulation, or manufacturing process patents, and whether Mylan challenged validity or non-infringement. Those details are not included.
Which patents did Pfizer assert against Mylan in 1:15-cv-00960?
An “asserted patents” table is the minimum for a patent litigation analysis. The prompt does not list:
- patent numbers
- listed inventors and assignees
- grant and expiration dates
- claims for each patent
- how each patent maps to the accused product or use
No reliable patent list can be created.
What is the procedural timeline for 1:15-cv-00960 (filing, motions, claim construction, trial dates)?
A litigation timeline must be grounded in docket entries: complaint filing date, answer date, scheduling order dates, claim construction events, summary judgment decisions, and final judgment or dismissal.
None of those docket events are provided, so a complete and accurate procedural timeline cannot be produced.
Was there a Markman/claim construction phase?
Claim construction outcomes often determine infringement/validity posture. Docket-specific scheduling and order dates are missing.
Were there summary judgment rulings or Daubert motions?
Without the docket’s motion practice record, the disposition cannot be summarized.
What was the outcome of Pfizer v. Mylan Laboratories Ltd. (1:15-cv-00960)?
A litigation outcome requires one of:
- final judgment on infringement and validity
- partial judgments
- stipulations of dismissal
- settlement with license terms (including effective dates and manufacturing carveouts)
- later procedural dispositions (withdrawal, amended complaint, consent judgment)
No final disposition facts are provided.
Was there a settlement or consent judgment in 1:15-cv-00960, and what were the terms?
To analyze settlement risk for generics, the record must include:
- whether it included a reverse-payment-style settlement (or business terms that function similarly)
- whether there was an agreed launch date
- any “carveouts” for certain dosages, strengths, NDCs, or formulations
- license scope and sublicensing limits
- whether approval was delayed by agreed statutory exclusivity offsets
No settlement terms are included, so a terms analysis cannot be done.
How does 1:15-cv-00960 affect generic launch timelines and Paragraph IV risk?
Paragraph IV cases hinge on:
- whether patents were adjudicated or found likely to be infringed
- whether the case settled before judgment
- whether any injunction or launch trigger applied
- the statutory 30-month stay implications under 21 U.S.C. § 355(j)
The prompt does not identify the underlying ANDA, the 30-month stay status, or any court-ordered effective dates.
What launch design-arounds did the case target?
Design-around success depends on product-specific facts (active ingredient form, polymorph, excipient system, particle size, dosage form, and process). None are provided.
What FDA regulatory status and Orange Book listings relate to this litigation?
A credible Orange Book analysis requires:
- the brand name, reference listed drug (RLD)
- Orange Book US patents and exclusivities listed at the time of the ANDA
- which patents were certified under Paragraph IV
- any “carveout” patents relevant to the final approval status
No RLD, NDC, or Orange Book listing set is supplied.
How strong is Pfizer’s patent estate in this case?
Patent strength analysis requires, at minimum:
- the asserted patents’ remaining life as of filing and as of any judgment/settlement
- prosecution history or claim breadth considerations
- claim construction results
- validity challenges and outcomes
None of those inputs appear in the prompt.
What companies were involved besides Pfizer and Mylan, and what roles did they play?
Corporate structure matters for enforcement and for follow-on licensing. A case caption alone does not identify:
- the ANDA applicant (which Mylan entity or affiliate)
- any additional defendants
- any sublicensees or co-plaintiffs/co-inventors
- any third-party manufacturers
No additional parties are listed in the prompt.
How does this case compare with other Pfizer v. generic litigation risks in 2015?
Comparative analysis requires a list of:
- other Pfizer cases against the same generic manufacturer(s)
- same patent families across different products
- patterns in asserted claims and typical outcomes
No comparative dataset is provided, and inventing one would not be accurate.
Key Takeaways
- No case-specific litigation facts are provided in the prompt beyond the docket number and party names.
- A complete litigation summary and IP analysis requires asserted patents, procedural history, and outcome, none of which are included.
- An accurate, business-usable assessment of launch impact, settlement terms, and patent strength cannot be generated from the information given.
FAQs
- What information does a docket number (1:15-cv-00960) alone confirm in Hatch-Waxman litigation?
- How are Paragraph IV certifications tied to specific patents in generic infringement cases?
- What docket events most strongly predict whether a case ends in a settlement vs. judgment?
- How do claim construction outcomes typically affect infringement and validity in ANDA cases?
- What Orange Book data points are required to connect a lawsuit to the exact FDA application?
References
- No citable sources were provided in the prompt.
